PREDNICARBATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDNICARBATE (PREDNICARBATE).
Prednicarbate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes.
| Metabolism | Prednicarbate is hydrolyzed in the skin to its active metabolite, prednisolone, which is further metabolized via hepatic pathways, primarily by CYP3A4. |
| Excretion | Primarily renal (<2% unchanged) and fecal (biliary excretion of metabolites) |
| Half-life | Terminal elimination half-life: approximately 1-2 hours; clinical context: short half-life supports topical use with minimal systemic accumulation |
| Protein binding | ~85% bound to albumin and corticosteroid-binding globulin |
| Volume of Distribution | Approximately 0.3 L/kg, indicating distribution primarily into extracellular fluid |
| Bioavailability | Topical: low systemic bioavailability (<1% through intact skin); oral: not applicable; no parenteral formulation |
| Onset of Action | Topical: within hours; clinical improvement typically observed within 3-7 days |
| Duration of Action | Duration of clinical effect: up to 12 hours; applied twice daily for dermatologic conditions |
| Molecular Weight | 488.6 |
Topical: apply sparingly to affected area twice daily; maximum 50 g per week.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment; systemic absorption is minimal. |
| Pediatric use | Children >1 year: apply sparingly to affected area twice daily; limit treatment to 2 weeks; avoid occlusive dressings. Use lowest potency and shortest duration. |
| Geriatric use | Use with caution due to thinner skin; apply sparingly for shortest duration necessary; avoid large body surface area use. |
| 1st trimester | Avoid unless essential; limited human data; animal studies show teratogenicity at high doses. Corticosteroids may increase risk of oral clefts (odds ratio ~1.3-3.4). |
| 2nd trimester | Use only if clearly needed; monitor for intrauterine growth restriction and adrenal suppression in neonate. |
| 3rd trimester | Use with caution; prolonged use may cause adrenal suppression in neonate; avoid high doses near term. |
Clinical note
Comprehensive clinical and safety monograph for PREDNICARBATE (PREDNICARBATE).
| Placental transfer | Prednicarbate is a corticosteroid; placental transfer is limited due to metabolism by 11β-HSD2, but at high doses some transfer may occur. Human data limited. |
| Breastfeeding | Prednicarbate is a topical corticosteroid; however, systemic absorption from topical use is minimal. Caution if applied to large areas or broken skin. Use lowest potency for shortest duration. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to prednicarbate or any componentUntreated bacterial, fungal, or viral skin lesionsPerioral dermatitisRosacea
| Precautions | Systemic absorption may occur with prolonged use, especially on large surface areas, under occlusion, or on broken skin, leading to HPA axis suppression., Local adverse reactions include skin atrophy, telangiectasias, striae, and contact dermatitis., Use with caution in patients with skin infections, as corticosteroids may mask or worsen infections., Pediatric patients may be more susceptible to systemic toxicity due to higher skin-to-body mass ratio. |
| Food/Dietary | No clinically significant food interactions have been reported. However, if used on large surface areas or with occlusion, systemic absorption may be enhanced, but this is not food-dependent. No dietary restrictions are necessary. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Prednicarbate is a topical corticosteroid. Systemic absorption is minimal, but first trimester use may slightly increase risk of oral clefts (OR 1.3-1.7). Second and third trimester use: no increased risk of major malformations, but possible intrauterine growth restriction with prolonged high-dose use. Limited data; overall risk low. |
| Fetal Monitoring | Monitor fetal growth with serial ultrasound if prolonged use over large body surface area; assess for signs of maternal adrenal suppression (rare with typical use). |
| Fertility Effects | No known effect on fertility in humans. Animal studies not reported with prednicarbate; topical corticosteroids generally show no effect on fertility. |
| Clinical Pearls | Prednicarbate is a non-halogenated corticosteroid with a high therapeutic index; it is preferred for use on face, intertriginous areas, and in children due to lower risk of atrophy. Ointment formulations provide better occlusion and absorption; avoid application to large body surface areas or prolonged use without supervision due to potential systemic absorption. Do not use for rosacea, perioral dermatitis, or fungal infections without concomitant antifungal therapy. |
| Patient Advice | Apply a thin layer only to affected areas, usually 1-2 times daily; do not use for more than 2 consecutive weeks unless directed. · Avoid covering the treated area with bandages or tight dressings unless instructed by your doctor. · Do not use this medication on the face, groin, or armpits for extended periods unless specifically directed. · Wash hands after application unless you are treating the hands. · Do not stop abruptly; taper use under medical guidance if used for a long time. · Inform your doctor if you develop signs of infection, skin thinning, or systemic effects like unusual weight gain. |